$ASRT News
Last published 3mo ago
- 3mo agoNSRXASRTNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic GrowthGlobeNewswireTEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development
- 4mo agoASRTAssertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027Business WireAssertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today announced the successful completion of its previously announced merger (the "Merger") with Zydus Lifesciences Ltd. ("Zydus Lifesciences")
- 6mo agoASRTAssertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in CashBusiness WireAll-Cash Tender Offer of $23.50 per share or $166.4 Million Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price Assertio Holdings, Inc. (NASDAQ:ASRT)
- 6mo agoASRTAssertio and Garda Mutually Agree to Delay Launch of Tender OfferBusiness WireAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to delay the launch of the previously announced tender
- 6mo agoASRTAssertio and Garda Mutually Agree to Postpone Commencement of Tender OfferBusiness WireAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to postpone the commencement of the previously
- 6mo agoASRTAssertio Announces Amended and Restated Merger Agreement with Garda TherapeuticsBusiness WireIncreased All-Cash Tender Offer Price of $21.80 per share – or $153.2 Million New Tender Offer Price Represents 21.1% Premium to Prior Offer Assertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today
- 6mo agoASRTAssertio and Garda Mutually Agree to Extend Tender Offer DeadlineBusiness WireAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to extend the deadline to commence the previously
- 6mo agoASRTAssertio Provides Update on Garda Therapeutics Tender ProcessBusiness WireAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today provided an update that Garda Therapeutics, Inc. ("Garda") intends to commence the tender offer to acquire all outstanding shares of Assertio on
- 7mo agoASRTHLNECosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from AssertioBusiness Wire-- Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence -- -- SYMPAZAN® Establishes a Neurology Rare Disease Footprint within Cosette -- -- Additional
- 7mo agoASRTAssertio Announces Agreement to be Acquired by Garda TherapeuticsBusiness WireAll-Cash Tender Offer of $18 per share – or $125.1 Million – Plus Contingent Value Right Tender Offer Price Represents 34.6% Premium to Unaffected Price and 46.6% Premium to Unaffected 30-day Volume-Weighted Average
- 8mo agoASRTAssertio Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireDelivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026 Assertio Holdings, Inc. ("Assertio" or the
- 8mo agoASRTAssertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026Business WireAssertio Holdings, Inc. ("Assertio") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its
- 10mo agoASRTAssertio Holdings, Inc. Regains Compliance With Nasdaq Listing RequirementsBusiness WireAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with all
- 10mo agoASRTAssertio Announces Publication of Rolvedon® Same-Day Dosing Clinical TrialBusiness WirePeer-reviewed publication in "The Oncologist" is now available online Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day dosing Assertio
- 10mo agoASRTAssertio Holdings, Inc. Announces 1-for-15 Reverse Stock SplitBusiness WireAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the "Certificate of Amendment") on December 19 to
- 1y agoASRTAssertio Reports Third Quarter 2025 Financial ResultsBusiness WireAdvanced Integration Efforts to Consolidate Subsidiaries and Pulled Forward Two Quarters of Rolvedon Demand Promotes Paul Schwichtenberg to President and COO Narrows FY2025 Net Product Sales Guidance Range to $110
- 1y agoASRTAssertio Announces Leadership TransitionGlobeNewswireAppoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at
- 1y agoASRTAssertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIVGlobeNewswireNew data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data
- 1y agoASRTAssertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological AssociationGlobeNewswirePoster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or
- 1y agoASRTAssertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025GlobeNewswireLAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) announced that members of its management team will host investor meetings at two investor
- 1y agoASRTAssertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoASRTAssertio Reports Second Quarter 2025 Financial ResultsGlobeNewswireSecond Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025
- 1y agoASRTAssertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025GlobeNewswireLAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11,
- 1y agoASRTAssertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025GlobeNewswireLAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the virtual
- 1y agoASRTAssertio Reports First Quarter 2025 Financial ResultsGlobeNewswireFirst Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value
- 1y agoASRTAssertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025GlobeNewswireLAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025,
- 1y agoASRTAssertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025GlobeNewswireLAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha
- 1y agoASRTAssertio Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireFourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of
- 1y agoASRTAssertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025GlobeNewswireLAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2024 financial results on
- 1y agoASRTAssertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireLAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 1y agoASRTAssertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of DirectorsGlobeNewswireLAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 1y agoASRTAssertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical StudyGlobeNewswireLAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 1y agoASRTAssertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCOGlobeNewswireLAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 1y agoASRTBEAMBeam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerGlobeNewswireCAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan
- 1y agoASRTApproval of Cambia, Nda #022165 (Labeling)FDA Approved DrugsApproval Date: 11/21/2024; Drug Name: Cambia, Nda #022165; Active Ingredients: DICLOFENAC POTASSIUM; Company: Assertio; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022165
- 1y agoASRTApproval of Zipsor, Nda #022202 (Labeling)FDA Approved DrugsApproval Date: 11/21/2024; Drug Name: Zipsor, Nda #022202; Active Ingredients: DICLOFENAC POTASSIUM; Company: Assertio; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022202
- 1y agoASRTBuxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at AssertioBusiness WireRequests that Senate Committee on Health, Education, Labor & Pensions Investigate Evident Falsification of Data Submitted to FDA and Potential Harm to Cancer Patients Abrupt Resignations by Assertio Board Members
- 2y agoASRTAssertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoASRTAssertio Reports Third Quarter 2024 Financial ResultsGlobeNewswireThird Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) --
- 2y agoASRTBuxton Helmsley Releases Evidence of Product-Related Fraud at AssertioBusiness WireEvidence Corroborates Allegations of Multiple Former Executives Calls on Assertio Board to Release Full Investigation Report and Supporting Materials The Buxton Helmsley Group, Inc. (together with certain of its
- 2y agoASRTAssertio Provides Response to Letter from Short-sellerGlobeNewswireClaims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Taking Legal and
- 2y agoASRTBuxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related FraudBusiness WireWell-Documented Evident Product-Related Fraud Related to the Acquisition of Spectrum Pharmaceuticals' Rolvedon Biologic Illuminates the Basis for Assertio's Massive Write-Down of Spectrum Immediately After
- 2y agoASRTAssertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024GlobeNewswireLAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 2y agoASRTAssertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024GlobeNewswireLAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 2y agoASRTAssertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireLAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 2y agoASRTAssertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024GlobeNewswireLAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 2y agoASRTAssertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoASRTAssertio Reports Second Quarter 2024 Financial ResultsGlobeNewswireSecond Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4
- 2y agoASRTAssertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024GlobeNewswireLAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
- 2y agoASRTFOSLBuxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.Business WireCalls for the Immediate Resignation of Four Directors, Including Chairman Peter Staple, Heather Mason, William McKee and Dr. Jeffrey Vacirca Intends to Nominate Independent, Qualified Directors at the Company's Next